2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Gene Editing, Treatment Considerations, Biological Therapies, Bispecific Antibody Therapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Health Economics, Quality of Care, Diseases, Immunology, Autoimmune Disorders, GVHD, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Epidemiology, Real-World Evidence, Study Population, Human, Adult
PAPER

1216 IKK inhibitor-mediated NF‑κB pathway blockade ameliorates disease manifestations and inflammation in hemophagocytic lymphohistiocytosis

Yijun Wu, MD, Xu Sun, PhD2, Kai Kang, MD3, Yang Dai, MD4, Ailin Zhao, PhD5, Ting Niu6
1 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University., Chengdu, China
2 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University., Chengdu, China
3 West China Hospital, Sichuan University., Chengdu, China
4 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University., Chengdu, China
5 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University., Chengdu, China
6 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University., Chengdu, China

Background: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome driven by uncontrolled immune activation, with persistent aberrant NF-κB signaling as a central pathogenic hub. Despite this, no direct NF-κB-targeted therapy is currently available. This study aimed to systematically evaluate the therapeutic efficacy of a selective IKK inhibitor in both primary and secondary HLH mouse models and to preliminarily elucidate its mechanisms of action, thereby providing preclinical evidence for NF-κB-directed HLH treatment.

Methods: We employed two well-established murine models: a primary HLH model (perforin-deficient mice infected with lymphocytic choriomeningitis virus) and a secondary HLH model (macrophage hyperactivation-induced). Dose-escalation experiments were performed to establish the safe and tolerable dose range of the IKK inhibitor (BMS-345541). At the optimal effective dose, we comprehensively assessed its effects on HLH-associated clinical signs, hematological parameters, histopathological changes, and systemic inflammatory responses. Mechanistic exploration focused on transcription factor translocation, immune cell subset dynamics, and effector functions, with comparative analyses across the two pathological contexts.

Results: Within a clearly defined safety window, the IKK inhibitor was well tolerated and profoundly reversed the core disease phenotypes in both primary and secondary HLH models. It effectively corrected pancytopenia, with significant increases in hemoglobin, white blood cell, and platelet counts; markedly reduced hepatosplenomegaly; and lowered serum transaminase levels. Histopathological examination confirmed that the inhibitor attenuated hepatic inflammatory infiltration and necrosis, and ameliorated splenic architectural disruption. Multiplex cytokine assays revealed broad suppression of the characteristic HLH-associated cytokine storm, with substantial reductions in TNF-α, IFN-γ, IL-10, and the chemokines CCL-3, CCL-4, and CXCL-9. Mechanistically, the IKK inhibitor blocked nuclear translocation of both p65 and RelB, thereby inhibiting canonical and non-canonical NF-κB signaling. However, its downstream effects were subtype-dependent: in secondary HLH, it preferentially eliminated inflammatory monocytes; in primary HLH, it predominantly reduced pathogenic CD8? T cells, including effector memory subsets, and suppressed their IFN-γ-producing capacity. These findings reveal that the NF-κB pathway drives HLH pathology through distinct immune effectors depending on the disease subtype.

Conclusions: This study provides the first systematic evidence that an IKK inhibitor targeting the NF-κB pathway exerts robust therapeutic effects in both primary and secondary HLH models, not only alleviating systemic inflammation and organ damage but also differentially reshaping immune homeostasis according to disease etiology. Our findings establish NF-κB signaling as a viable and druggable target in HLH and offer a foundation for developing subtype-specific precision therapeutic strategies for this devastating syndrome..

Yijun Wu, MD: No relevant conflicts of interest to declare.